Hypothesis

Chronic sleep restriction diminishes glymphatic influx, allowing accumulation of specific circulating metabolites (e.g., adenosine, kynurenine, and exosomal miR‑155) that directly blunt erythropoietin (EPO) signaling in bone‑marrow erythroid progenitors. Restoring glymphatic flow rescues EPO‑JAK2‑STAT5 phosphorylation and improves erythropoiesis without altering EPO levels.

Rationale

• During slow‑wave sleep, glymphatic flux increases up to two‑fold, clearing metabolic waste via aquaporin‑4 (AQP4)‑dependent CSF‑interstitial exchange [1].
• Systemic autophagy, also sleep‑enhanced, degrades protein aggregates and damaged mitochondria [2].
• Sleep loss triggers epigenetic reprogramming of hematopoietic stem and progenitor cells (HSPCs) toward myeloid bias and reduces clonal diversity [3] and shifts mesenchymal stromal niches from osteogenic to adipogenic [4]—both favoring inflammation.
• The suprachiasmatic nucleus drives sympathetic rhythms that regulate HSPC mobilization and differentiation [5]. Disrupted sleep uncouples this circuit, amplifying niche‑derived inflammatory signals [6, 7].

These pathways converge on bone‑marrow dysfunction, yet no study has directly tied glymphatic clearance deficits to erythropoietin sensitivity. We propose that the glymphatic system does more than remove bulk waste; it selectively extracts metabolites that inhibit the EPO receptor‑JAK2‑STAT5 axis in early erythroid progenitors.

Novel Mechanistic Insight

1. Adenosine buildup – Adenosine, a sleep‑pressure molecule, accumulates in extracellular fluid when glymphatic clearance falters. High adenosine engages A2A receptors on erythroid progenitors, raising cAMP and activating phosphodiesterases that dampen JAK2 phosphorylation [8].
2. Kynurenine pathway shift – Sleep loss elevates plasma kynurenine, which binds aryl hydrocarbon receptor (AhR) in erythroid cells, driving transcription of oxidative‑stress genes that antagonize STAT5 nuclear translocation [9].
3. Exosomal miR‑155 – Astrocyte‑derived exosomes enriched in miR‑155 are normally flushed via glymphatic flow. When clearance drops, these exosomes home to bone marrow, where miR‑155 suppresses Epor mRNA translation and promotes SOCS1 expression, creating a refractory state [10].

Collectively, these factors create a biochemical milieu that uncouples circulating EPO levels from intracellular signaling, producing functional EPO resistance despite normal hormone concentrations.

Testable Predictions

1. Correlation – In mice subjected to 4 weeks of chronic sleep restriction (CSR), glymphatic influx measured by intrathecal CSF‑traced gadolinium MRI will inversely correlate with bone‑marrow interstitial adenosine, kynurenine, and miR‑155‑exosome levels.
2. Signaling defect – Erythroid progenitors (Ter119⁺CD71⁺) from CSR mice will show reduced STAT5 phosphorylation (pSTAT5) after ex vivo EPO stimulation, while total EpoR protein remains unchanged.
3. Rescue via glymphatic enhancement – Pharmacological boost of CSF flow (e.g., low‑dose acetazolamide or intrathecal VEGF‑A) or genetic overexpression of AQP4 in astrocytes will normalize metabolite levels, restore pSTAT5 response, and increase hemoglobin and reticulocyte counts without altering serum EPO.
4. Falsification – If enhancing glymphatic flow fails to improve EPO‑STAT5 signaling or erythropoietic output despite clearing metabolites, the hypothesis is refuted.

Experimental Outline

• Animal model: C57BL/6J mice, 8 weeks old, split into control, CSR (4 h/night), CSR + glymphatic enhancer, and CSR + enhancer + metabolite scavenger groups.
• Glymphatic measurement: Intrathecal injection of fluorescently labeled albumin; quantify brain clearance via two‑photon imaging and CSF‑blood metabolite ratios.
• Metabolite profiling: LC‑MS of CSF and bone‑marrow interstitial fluid for adenosine, kynurenine; qPCR for miR‑155 in isolated exosomes.
• EPO signaling assay: Flow cytometric pSTAT5 staining of sorted erythroid progenitors after 15 min EPO (5 U/mL) ex vivo.
• Physiological readouts: Serum EPO (ELISA), hemoglobin, hematocrit, reticulocyte count, colony‑forming unit‑erythroid (CFU‑E) assays.
• Statistical plan: Two‑way ANOVA with post‑hoc Tukey; power analysis targeting n = 8 per group for 80 % power to detect 20 % pSTAT5 change.

Impact

Confirming that sleep‑regulated glymphatic clearance directly modulates erythropoietic sensitivity would reposition sleep therapy as a mechanistic intervention for anemia of aging, chronic inflammation, or chemotherapy‑induced erythropoietic failure. It would also provide a biomarker framework—glymphatic efficiency coupled with circulating inhibitory metabolites—to predict EPO responsiveness in clinical settings.